Streetbeat News

Analyst Ratings

GIII

G-III Apparel Group reported strong Q2 FY24 earnings with sales growth of 9% YoY to $659.76 million, beating the analyst consensus. Gross profit rose 20.8% YoY to $276.6 million. Despite this, Telsey Advisory Group reiterated the Market Perform rating on G-III Apparel with the same price target of $22. The analyst praised GIII's efforts to grow its DTC penetration and strengthen its owned brand portfolio but expressed concern about GIII's wholesale exposure in the current operating environment.

Portfolio Pulse from Nabaparna Bhattacharya

September 08, 2023 | 7:20 pm

TEVA

Bank of America Securities has maintained a Buy rating on Teva Pharmaceutical Industries Ltd. This has resulted in a rise in Teva's stock prices.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 7:17 pm

WFC

Wells Fargo's (NYSE:WFC) short percent of float has fallen 3.61% since its last report, with 29.30 million shares sold short, which is 0.8% of all regular shares available for trading. This decrease in short interest could signal a more bullish sentiment towards the stock. Compared to its peers, Wells Fargo has less short interest as a percentage of float, with the average being 0.85%.

Portfolio Pulse from Benzinga Insights

September 08, 2023 | 7:15 pm

BKR

Baker Hughes's (NYSE:BKR) short percent of float has fallen 6.3% since its last report, with 14.91 million shares sold short, which is 2.23% of all regular shares available for trading. It would take traders 2.84 days to cover their short positions on average. Compared to its peers, Baker Hughes has less short interest as a percentage of float, with an average of 5.53%.

Portfolio Pulse from Benzinga Insights

September 08, 2023 | 7:15 pm

BRZE

Oppenheimer analyst Brian Schwartz maintains an 'Outperform' rating on Braze (NASDAQ:BRZE) and raises the price target from $42 to $52.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 7:10 pm

FRSH

Oppenheimer analyst Brian Schwartz maintains an Outperform rating on Freshworks (NASDAQ:FRSH) and raises the price target from $23 to $26.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 7:09 pm

SMAR

Barclays analyst Ryan Macwilliams maintains an Equal-Weight rating on Smartsheet (NYSE:SMAR) and raises the price target from $45 to $50.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 7:08 pm

JNJ

Barclays analyst Matt Miksic has maintained an Equal-Weight rating on Johnson & Johnson (NYSE:JNJ) but lowered the price target from $175 to $158.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 7:02 pm

FRSH

Barclays analyst Raimo Lenschow maintains an Equal-Weight rating on Freshworks (NASDAQ:FRSH) and raises the price target from $20 to $25.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 7:01 pm

REGN

A significant number of investors have taken a bearish stance on Regeneron Pharmaceuticals (NASDAQ:REGN), with 70% of detected trades showing bearish expectations. The targeted price range for REGN over the last 3 months is $560.0 to $960.0. The current price of REGN is up 1.0% at $833.48. Major financial institutions such as Wells Fargo, Oppenheimer, Barclays, RBC Capital, and BMO Capital have maintained positive ratings on REGN, with price targets ranging from $830 to $1050.

Portfolio Pulse from Benzinga Insights

September 08, 2023 | 7:01 pm